Okyo Pharma Ltd. is a biopharmaceutical company engaged in the development of novel therapies for eye disorders, including dry eye disease and ocular inflammation. Focusing on the ophthalmology sector, Okyo Pharma leverages advanced technologies to create solutions that address unmet medical needs in eye health. The company’s research-driven approach has led to the identification of innovative drug candidates designed to enhance eye care treatments. Okyo Pharma's pipeline includes preclinical and clinical-stage projects aimed at improving patient outcomes through innovative formulations that deliver therapeutic efficacy with minimal side effects. In the financial markets, Okyo Pharma represents a key player within the biotechnology industry, consistently contributing to advances in medical technology and drug development. Its endeavors not only hold significance for healthcare providers and patients but also invite interest from biotechnology investors and stakeholders aiming to support the advancement of medical sciences.